Physician profile
Norman Latov
NPI 1003994708
$45,064.06
in general payments reported to CMS, 2019-2025
7 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.80 · 2021: $3,128 · 2022: $16K · 2023: $3,548 · 2024: $2,500 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $3,068 · Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,630.50 |
| Travel and Lodging | $3,068.37 |
| Food and Beverage | $581.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $12,084.14 | 2024-2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $11,811.69 | 2021-2023 | |
| Pfizer INC. | $8,100.00 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $4,548.43 | 2025 | |
| Ipsen Bioscience INC. | $4,500.00 | 2022 | |
| Grifols Shared Services North America, INC. | $4,000.00 | 2022 | |
| Akcea Therapeutics, INC. | $19.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Latov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.